Quanterix Corp (QTRX) Stock Price, Quote & News

Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Sim...

Industry: Medical Devices

Sector: Healthcare

Phone: 617 301 9400

Website: www.quanterix.com

Address:

Building 1, 900 Middlesex Turnpike, Billerica, United States

SQUEAKSBANDIT Feb. 23 at 4:37 PM

$QTRX huge block nearly 700k shares crossed @ 5.60 nearly 1.5% of total shares outstanding

0 · Reply

Rufusbird Feb. 23 at 1:46 PM

$QTRX Alzheimer testing with blood tests on Mainstream Fox News this morning See: https://www.foxnews.com/health/blood-test-could-predict-when-alzheimers-symptoms-start-years-advance

0 · Reply

Rufusbird Feb. 20 at 2:34 PM

$QTRX After riding through the down cycle, it is fun owning QTRX again! Let er run!

0 · Reply

DarkScanner Feb. 18 at 7:05 AM

$QTRX Quanterix provides life sciences tools with Simoa immunoassay platform, facing growth tied to biopharma R&D and academic funding [citation:historical].

0 · Reply

SQUEAKSBANDIT Feb. 17 at 9:06 PM

$QTRX the merger consumed the bulk of 2025 from the time it was announced till now the shareprice was more than halved now its time to execute $10 sometime this calendar year isn't out of the question

0 · Reply

FrostFuzz Feb. 12 at 10:24 PM

$QTRX

0 · Reply

MaryMiceli912 Feb. 11 at 2:35 PM

$QTRX Quanterix; life sciences tools (immunoassay); growth tied to biopharma R&D and academic funding; adoption of Simoa platform is key.

0 · Reply

ZacksResearch Feb. 4 at 6:13 PM

$QTRX just took a big regulatory step in Alzheimer’s testing. 🧠📄 Quanterix submitted a 510(k) to the FDA for its multi-analyte blood test designed to help evaluate cognitive symptoms for possible Alzheimer’s disease — a notable milestone in its diagnostic push. See why this filing matters and what comes next 👉 https://www.zacks.com/stock/news/2829232/quanterix-submits-fda-510k-for-multi-analyte-alzheimers-blood-test?cid=sm-stocktwits-2-2829232-teaser-32033&ADID=SYND_STOCKTWITS_TWEET_2_2829232_TEASER_32033

0 · Reply

ZacksResearch Feb. 4 at 5:13 PM

$QTRX drops after FDA submission news — why the market's missing the bigger picture! 🤔 Despite a 0.8% dip, QTRX's multi-analyte blood test for Alzheimer's could be a game-changer. The 510(k) submission, backed by extensive validation, positions Quanterix for growth in the Alzheimer’s market, valued at $7.72 billion in 2025 and projected to grow at a 9% CAGR through 2032. 📈 Discover the strategic impact here 👉 https://www.zacks.com/stock/news/2829232/quanterix-submits-fda-510k-for-multi-analyte-alzheimers-blood-test?cid=sm-stocktwits-2-2829232-body-32021&ADID=SYND_STOCKTWITS_TWEET_2_2829232_BODY_32021

0 · Reply

Rufusbird Feb. 2 at 3:11 PM

$QTRX I sold all of my Niagen Bioscience shares and bought QTRS with the $

1 · Reply

Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026

Feb 3, 2026, 8:33 AM EST - 20 days ago

Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer's Disease Detection

Jan 21, 2026, 8:33 AM EST - 4 weeks ago

Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer's Risk Profiling

Jan 16, 2026, 4:01 PM EST - 5 weeks ago

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 8, 2026, 4:30 PM EST - 6 weeks ago

Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

Dec 22, 2025, 7:30 AM EST - 2 months ago

Quanterix Announces Landmark Nature Study Redefining Alzheimer's Disease Neuropathology Prevalence

Nov 20, 2025, 4:15 PM EST - 3 months ago

Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

Nov 17, 2025, 5:30 PM EST - 3 months ago

Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring

Nov 10, 2025, 7:11 PM EST - 3 months ago

Quanterix Corporation (QTRX) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 4:01 PM EST - 3 months ago

Quanterix Releases Financial Results for the Third Quarter of 2025

Nov 3, 2025, 7:00 AM EST - 4 months ago

Quanterix To Report Third Quarter 2025 Financial Results on November 10, 2025

Aug 21, 2025, 4:30 PM EDT - 6 months ago

Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit

Aug 11, 2025, 7:00 AM EDT - 7 months ago

Quanterix to Present at the Canaccord Genuity 45th Annual Growth Conference

Aug 9, 2025, 2:27 AM EDT - 7 months ago

Quanterix Corporation (QTRX) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:06 PM EDT - 7 months ago

Quanterix Releases Financial Results for the Second Quarter of 2025

Aug 4, 2025, 4:02 PM EDT - 7 months ago

Quanterix To Report Second Quarter 2025 Financial Results on August 7, 2025

Aug 4, 2025, 9:30 AM EDT - 7 months ago

Quanterix Announces Cooperation Agreement with Kent Lake Capital

Jul 28, 2025, 7:00 AM EDT - 7 months ago

Quanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAIC

Jul 8, 2025, 9:07 AM EDT - 8 months ago

Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum

Jun 23, 2025, 7:30 AM EDT - 8 months ago

Quanterix Expands Reach with IVD and Large Reference Labs

Jun 11, 2025, 8:00 AM EDT - 9 months ago

Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders

Jun 6, 2025, 9:41 AM EDT - 9 months ago

Quanterix to Present at Goldman Sachs Global Healthcare Conference

May 23, 2025, 2:21 PM EDT - 9 months ago

Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

AKYA

May 12, 2025, 11:19 PM EDT - 10 months ago

Quanterix Corporation (QTRX) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 10 months ago

Quanterix Releases Financial Results for the First Quarter of 2025

May 7, 2025, 3:46 PM EDT - 10 months ago

AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA

AKYA

May 5, 2025, 7:00 AM EDT - 10 months ago

Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025

Apr 30, 2025, 8:00 AM EDT - 10 months ago

Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders

AKYA

Apr 29, 2025, 7:00 AM EDT - 10 months ago

Quanterix and Akoya Biosciences Announce Amended Merger Agreement

AKYA

Apr 17, 2025, 8:30 AM EDT - 11 months ago

Kent Lake Files Definitive Proxy Statement and Sends Letter to Quanterix Shareholders

Apr 14, 2025, 8:00 AM EDT - 11 months ago

Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences

AKYA

Apr 7, 2025, 8:15 AM EDT - 11 months ago

Kent Lake Comments on Quanterix's Value Destructive Bridge Financing for Financially Troubled Akoya

AKYA

Apr 1, 2025, 1:00 AM EDT - 11 months ago

Quanterix Showcases Innovation Powered by Simoa® at AD/PD with Customer Research and New Dried Blood Spot Extraction Kit

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences

AKYA

Mar 17, 2025, 7:19 PM EDT - 1 year ago

Quanterix Corporation (QTRX) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 4:01 PM EDT - 1 year ago

Quanterix Releases Financial Results for the Fourth Quarter of 2024

Mar 17, 2025, 4:00 PM EDT - 1 year ago

Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today's Earnings Call

AKYA

Mar 13, 2025, 1:00 PM EDT - 1 year ago

Quanterix To Report Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Kent Lake Issues Investor Presentation Detailing Opposition to Quanterix's Proposed Merger with Akoya Biosciences

AKYA

Mar 3, 2025, 8:00 AM EST - 1 year ago

Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board

Mar 3, 2025, 6:00 AM EST - 1 year ago

Quanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition

Mar 2, 2025, 11:00 AM EST - 1 year ago

The Schall Law Firm Invites Shareholders With Losses In Quanterix Corporation To Join A Securities Fraud Investigation

Feb 19, 2025, 8:30 AM EST - 1 year ago

Neurogen Biomarking Announces Global Agreement with Quanterix for Use of Blood Biomarker Assay in its Patient-Initiated Blood Test to Support Early Detection of Dementia and Mild Cognitive Impairment Due to Alzheimer's Disease

Feb 18, 2025, 3:40 PM EST - 1 year ago

Kent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Company's Proposed Merger with Akoya Biosciences

AKYA

Feb 14, 2025, 5:48 PM EST - 1 year ago

Quanterix Corporation Announcement: If You Have Suffered Losses in Quanterix Corporation (NASDAQ: QTRX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Feb 5, 2025, 3:43 PM EST - 1 year ago

Quanterix Investor News: If You Have Suffered Losses in Quanterix Corporation (NASDAQ: QTRX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Feb 1, 2025, 11:00 AM EST - 1 year ago

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Quanterix Corporation For Securities Fraud

SQUEAKSBANDIT Feb. 23 at 4:37 PM

$QTRX huge block nearly 700k shares crossed @ 5.60 nearly 1.5% of total shares outstanding

0 · Reply

Rufusbird Feb. 23 at 1:46 PM

$QTRX Alzheimer testing with blood tests on Mainstream Fox News this morning See: https://www.foxnews.com/health/blood-test-could-predict-when-alzheimers-symptoms-start-years-advance

0 · Reply

Rufusbird Feb. 20 at 2:34 PM

$QTRX After riding through the down cycle, it is fun owning QTRX again! Let er run!

0 · Reply

DarkScanner Feb. 18 at 7:05 AM

$QTRX Quanterix provides life sciences tools with Simoa immunoassay platform, facing growth tied to biopharma R&D and academic funding [citation:historical].

0 · Reply

SQUEAKSBANDIT Feb. 17 at 9:06 PM

0 · Reply

FrostFuzz Feb. 12 at 10:24 PM

$QTRX

0 · Reply

MaryMiceli912 Feb. 11 at 2:35 PM

$QTRX Quanterix; life sciences tools (immunoassay); growth tied to biopharma R&D and academic funding; adoption of Simoa platform is key.

0 · Reply

ZacksResearch Feb. 4 at 6:13 PM

0 · Reply

ZacksResearch Feb. 4 at 5:13 PM

0 · Reply

Rufusbird Feb. 2 at 3:11 PM

$QTRX I sold all of my Niagen Bioscience shares and bought QTRS with the $

1 · Reply

IOMASS Jan. 27 at 7:11 PM

$QTRX Interesting trading volume today - down a bit with market but constructive...

0 · Reply

SuperGreenToday Jan. 24 at 12:22 AM

$QTRX Share Price: $6.49 Contract Selected: Aug 21, 2026 $10 Calls Buy Zone: $0.58 – $0.72 Target Zone: $1.06 – $1.29 Potential Upside: 72% ROI Time to Expiration: 209 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Swick02 Jan. 23 at 6:56 PM

$QTRX price is back down to where it was before the new CEO announcement. We also learned that revenues and the cash position are both above forecast for year end. Adding more exposure here on this pullback.

0 · Reply

sakuzoh Jan. 21 at 2:01 PM

$QTRX huge news https://www.stocktitan.net/news/QTRX/quanterix-announces-landmark-jama-study-highlighting-prognostic-sdqbd9t29qvi.html

0 · Reply

IOMASS Jan. 15 at 6:59 PM

$QTRX Don't need an activist at this stage as it appears QTRX is now positioned for growth/enhancing shareholder value but a smart guy entering the picture based on the new changes would help with credibility...

0 · Reply